USA flag logo/image

An Official Website of the United States Government

TAS::75 0849::TAS SBIR TOPIC 277 - NOVEL CTC-BASED TEST FOR LUNG CANCER DRUG…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
N43CO110109
Solicitation Year:
2011
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
CYNVENIO BIOSYSTEMS, INC.
2260 Townsgate Road WESTLAKE VILLAGE, CA 91361-2437
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: TAS::75 0849::TAS SBIR TOPIC 277 - NOVEL CTC-BASED TEST FOR LUNG CANCER DRUG RESISTANCE
Agency: HHS
Contract: N43CO110109
Award Amount: $195,030.00
 

Abstract:

The evolving understanding of cancer indicates every tumor has distinct characteristics driven by the molecular pathology of the disease. Predicted by this heterogeneity, targeted therapeutic agents are much more successful than a one size fits all approach. Currently, there are no tools to analyze resistance in solid tissue tumor cells other than biopsy. This limitation excludes test for molecular markers that emerge during treatment. The goal of this project is to develop and characterize a CTC based molecular drug resistance test and demonstrate application in clinical samples. 15-20% of non-small cell lung cancers are driven by activating mutations in the epidermal growth factor receptor (EGFR), a mutation that can be very effectively treated with EGFRinhibitors such as gefitinib or erlotinib. Resistance to these drugs arises universally; caused half of the time by a T790M mutation. Currently, resistance is determined medically by demonstrating tumor progression. As an alternative approach, extractingthe small numbers of circulating tumor cells (CTC) released into the bloodstream for detection of the emergence of the T790M mutation offers a strategy for genotyping patient-specific tumor cells in real time. This will produce a fundamentally enabling technology for predictive cancer tests in personalized medicine.

Principal Investigator:

Paul Dempsey
805-777-0017
PDEMPSEY@CYNVENIO.COM

Business Contact:

Paul Dempsey
805-777-0017
PDEMPSEY@CYNVENIO.COM
Small Business Information at Submission:

CYNVENIO BIOSYSTEMS, INC.
2260 TOWNSGATE RD UNIT 2 WESTLAKE VILLAGE, CA 91361-2437

EIN/Tax ID: 127159223
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No